Senzime contracts new CFO

Erik Berman, B Sc in Business Administration and Economics, with more than 30 years of experience from senior positions in small and medium-sized listed or private companies within Life Science. Erik comes from a position as CEO of the vaccine adjuvant company Novavax AB, and since autumn 2018 he has worked at Senzime to a lesser extent via his own company.

"I am pleased to welcome Erik to Senzime who is in an intense and exciting phase. Erik has a solid financial and strategic experience and a profile that fits well with Senzime with our strong focus on expansion and financial stability," says Pia Renaudin, Senzimes CEO.

For further information, please contact: 

Pia Renaudin, CEO of Senzime AB                                                                                                                 

Tel: +46 (0)70-813 34 17, email: pia.renaudin@senzime.com         

TO THE EDITORS

About Senzime

Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients' biochemical and physiological processes before, during and after surgery. The portfolio of technologies includes bedside systems that enable automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patients’ neuromuscular function perioperatively and in the intensive care medicine setting. The solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease health care costs. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on Nasdaq First North (ticker SEZI). FNCA Sweden AB, +46 (0)8-528 00 399, info@fnca.se, is Certified Adviser for Senzime. www.senzime.com